REPOSITIVE LIMITED: INTERNATIONAL DEVELOPMENT PROGRAMME TO INCREASE THE IMPACT OUR ONLINE PLATFORM FOR QUERYING AND ACCESS TO MOLECULAR DATA ON PATIENT DERIVED XENOGRAFT MODELS.

Patient derived xenograft (PDX) models are powerful tools used by scientists studying cancer and in

discovery of new cancer treatments. Each one is grown from a sample of a cancerous tumour donated by a

cancer sufferer: so they are precious, valuable and useful. But scientists find it hard to find suitable ones

for their work and so many spend a lot of time testing them, just to collect the same basic information over

and over again. Repositive is creating an online platform for scientists to find PDX models and data to

make sure that they are the best ones for their work. This project, costing £29,968 and lasting 3 months,

funds us build the platform with the help of PDX model providers and pharmaceutical companies who use

them often, and who will give us feedback on our concepts and designs. It will save 3 months of

development time and will enable us to make sure that they find the platform valuable and use it when it

is completed. In future it will help companies to save up to 6 months in drug discovery time, so that new

treatments can be identified and brought to market more quickly and at lower cost than now.